The NHS in England has struck a payment-by-results deal with a pharmaceutical company for the supply of a drug used to treat hepatitis C. It means the manufacturer will only be paid if a patient is successfully cured. The company and the drug have not been named due to commercial confidentiality, but the arrangement was confirmed by NHS England chief executive, Simon Stevens. If the innovative deal works well, it may be introduced for other costly treatments as the NHS seeks to reduce its £15bn ($20.3bn) annual bill for drugs.
The NHS in England has struck a payment-by-results deal with a pharmaceutical company for the supply of a drug used to treat hepatitis C. It means the manufacturer will only be paid if a patient is successfully cured. The company and the drug have not been named due to commercial confidentiality, but the arrangement was confirmed by NHS England's chief executive, Simon Stevens. If the innovative deal works well, it may be introduced for other costly treatments as the NHS seeks to reduce its £15bn ($20.3bn) annual bill for drugs.